Protein microarray platforms for clinical proteomics

Abstract

Proteomics for clinical applications is presently in a state of transition. It has become clear that the classical approaches based on 2-DE and/or MS need to be complemented by different kinds of technologies. The well-known problems include sample complexity, sensitivity, quantitation, reproducibility, and analysis time. We suggest that the new technologies for clinical proteomics can be supported by antibody-centric protein microarray platforms. These platforms presently include antibody microarrays and lysate, or reverse capture/reverse phase protein microarrays. Other forms of these arrays are in less mature developmental stages, including ORF and self assembling protein microarrays. Bioinformatic support for interpreting these arrays is becoming more available as the whole field of systems biology begins to mature. The present set of applications for these platforms is profoundly focused on certain common cancers, immunology, and cystic fibrosis. However, we predict that many more disease entities will become studied as knowledge of the power and availability of these platforms becomes more widely established. We anticipate that these platforms will eventually evolve to accommodate label-free detection technologies, human genome-scale numbers of analytes, and increases in analytic and bioinformatic speeds.

Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report

“…Intuitively, most clinical tests of biological fluids are based on the concentration of an analyte, not the total mass. Therefore, simply printing a sample, without concern for the included quantity of protein, is the recommended strategy (70,71). Secondly, if a fluorescent small molecule is included in the sample, a representation of the volume printed can be accurately determined on a fluorescent slide reader.…”

Challenges in cancer research and multifaceted approaches for cancer biomarker quest

“…Moreover, the advent of digital slide technology has afforded an unparalleled opportunity for archiving valuable histopathological and immunohistochemical specimens. Such digital images offer a unique opportunity to provide a paradigm shift in relation to interpretation of such data via the use of automated image analysis algorithms [58,59].…”

Proteinbiochips in der Biomedizin und Biotechnologie

“…Die Analyse derartiger Modifikationen mithilfe konventioneller, mit rekombinanten Proteinen beladener Mikroarrays ist problematisch, da ihre Einführung in diese Proteine durch Expression in Bakterien oder Hefen oft nicht möglich ist. [21] Daher sind RPPAs ein vielversprechendes Hilfsmittel für die klinische Diagnostik, das folgende Vorteile mit sich bringt: [22][23][24] 1) Es werden nur geringe Probenmengen benötigt. Die Detektion der Peptidbindung erfolgte durch Fluoreszenzmessungen.…”